3 research outputs found
Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells
Background: Understanding the signalling pathways involved in angiogenesis, and developing anti-angiogenic
drugs are one of the major focuses on cancer research. Herein, we assessed the effect of CPTH6, a lysine
acetyltransferase inhibitor and anti-tumoral compound, on angiogenesis-related properties of both endothelial and
cancer cells.
Methods: The in vitro effect of CPTH6 on protein acetylation and anti-angiogenic properties on endothelial and
lung cancer cells was evaluated via wound healing, trans-well invasion and migration, tube formation,
immunoblotting and immunofluorescence. Matrigel plug assay, zebrafish embryo and mouse xenograft models
were used to evaluate in vivo anti-angiogenic effect of CPTH6.
Results: CPTH6 impaired in vitro endothelial angiogenesis-related functions, and decreased the in vivo
vascularization both in mice xenografts and zebrafish embryos. Mechanistically, CPTH6 reduced α-tubulin
acetylation and induced accumulation of acetylated microtubules in the perinuclear region of endothelial cells.
Interestingly, CPTH6 also affected the angiogenesis-related properties of lung cancer cells, and conditioned media
derived from CPTH6-treated lung cancer cells impaired endothelial cells morphogenesis. CPTH6 also modulated the
VEGF/VEGFR2 pathway, and reshaped cytoskeletal organization of lung cancer cells. Finally, anti-migratory effect of
CPTH6, dependent on α-tubulin acetylation, was also demonstrated by genetic approaches in lung cancer cells.
Conclusion: Overall, this study indicates that α-tubulin acetylation could play a role in the anti-angiogenic effect of
CPTH6 and, more in general, it adds information to the role of histone acetyltransferases in tumor angiogenesis,
and proposes the inhibition of these enzymes as an antiangiogenic therapy of cancer
Genome-Wide DNA Methylation Profiling Solves Uncertainty in Classifying NSD1 Variants
Background: Inactivating NSD1 mutations causing Sotos syndrome have been previously associated with a specific genome-wide DNA methylation (DNAm) pattern. Sotos syndrome is characterized by phenotypic overlap with other overgrowth syndromes, and a definite diagnosis might not be easily reached due to the high prevalence of variants of unknown significance (VoUS) that are identified in patients with a suggestive phenotype. Objective: we performed microarray DNAm profiling in a set of 11 individuals with a clinical suspicion of Sotos syndrome and carrying an NSD1 VoUS or previously unreported variants to solve uncertainty in defining pathogenicity of the observed variants. The impact of the training cohort size on sensitivity and prediction confidence of the classifier was assessed. Results: The Sotos syndrome-specific DNAm signature was validated in six individuals with a clinical diagnosis of Sotos syndrome and carrying bona fide pathogenic NSD1 variants. Applying this approach to the remaining 11 individuals with NSD1 variants, we succeeded in confirming pathogenicity in eight subjects and excluding the diagnosis of Sotos syndrome in three. The sensitivity and prediction confidence of the classifier based on the different sizes of the training sets did not show substantial differences, though the overall performance was improved by using a data balancing strategy. Conclusions: The present approach solved uncertainty in cases with NDS1 VoUS, further demonstrating the clinical utility of DNAm profiling
Identification of a robust DNA methylation signature for Fanconi anemia
Fanconi anemia (FA) is a clinically variable and genetically heterogeneous cancer-predisposing disorder representing the most common bone marrow failure syndrome. It is caused by inactivating predominantly biallelic mutations involving >20 genes encoding proteins with roles in the FA/BRCA DNA repair pathway. Molecular diagnosis of FA is challenging due to the wide spectrum of the contributing gene mutations and structural rearrangements. The assessment of chromosomal fragility after exposure to DNA cross-linking agents is generally required to definitively confirm diagnosis. We assessed peripheral blood genome-wide DNA methylation (DNAm) profiles in 25 subjects with molecularly confirmed clinical diagnosis of FA (FANCA complementation group) using Illumina's Infinium EPIC array. We identified 82 differentially methylated CpG sites that allow to distinguish subjects with FA from healthy individuals and subjects with other genetic disorders, defining an FA-specific DNAm signature. The episignature was validated using a second cohort of subjects with FA involving different complementation groups, documenting broader genetic sensitivity and demonstrating its specificity using the EpiSign Knowledge Database. The episignature properly classified DNA samples obtained from bone marrow aspirates, demonstrating robustness. Using the selected probes, we trained a machine-learning model able to classify EPIC DNAm profiles in molecularly unsolved cases. Finally, we show that the generated episignature includes CpG sites that do not undergo functional selective pressure, allowing diagnosis of FA in individuals with reverted phenotype due to gene conversion. These findings provide a tool to accelerate diagnostic testing in FA and broaden the clinical utility of DNAm profiling in the diagnostic setting